Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Harnessing engineered mesenchymal stem cell-derived extracellular vesicles for innovative cancer treatments

Hwang WL., Huang SW., Hsiao AC., Chen CY., Hsu KF., Hsieh YT.

Narrative Review on Immune Modulation, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Stem Cell Res Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41254732
PMCID
PMC12625093
DOI
10.1186/s13287-025-04708-5
Citations
3

Abstract (original English)

Mesenchymal stem/stromal cells (MSCs) are known for their regenerative and immunomodulatory capabilities, which have made them the focus of extensive therapeutic research. A growing body of evidence underscores that mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have emerged as a promising cell-free platform that mimics the therapeutic benefits of MSCs while mitigating their associated risks. This review synthesizes recent advancements in bioengineering strategies aimed at enhancing the therapeutic efficacy, targeting specificity, and cargo-loading capacity of MSC-EVs for cancer treatment. These strategies include endogenous and exogenous modification approaches. Endogenous strategies involve genetically modifying parental MSCs or using environmental preconditioning to modulate the extracellular vesicles (EVs) content or surface proteins of EVs they produce. Exogenous techniques include post-isolation loading of therapeutic cargo, such as small interfering RNAs (siRNAs) and microRNAs (miRNAs), as well as EV membrane modifications. We also highlight key preclinical and clinical findings, addressing the dual role of MSC-EVs, which can be either pro- or anti-tumorigenic depending on the MSC tissue origin and the tumor microenvironment. Notably, EVs derived from human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) show the most consistent tumor-suppressive

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansNeoplasmsMicroRNAsTumor MicroenvironmentExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research